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Background: Statin-fibrate combination therapy has been used to treat patients with acute coronary syndrome
(ACS) complicated by elevated triglycerides (TG) and decreased high density lipoprotein cholesterol (HDL-C). The
purpose of this study was to evaluate the influence of the combination therapy on lipids profile and apolipoprotein
A5 (apoA5) level in patients with ACS.
Methods: One hundred and four patients with ACS were recruited and randomly assigned into two groups: one
was statin group (n = 52), given atorvastatin (20 mg QN) or other statins with equivalent dosages; the other was
combination group (n = 52), given the same dose of statin plus bezafibrate (200 mg BID). Follow-up visits were
scheduled at the end of 6 and 12 weeks post treatment. Serum apoA5 levels were determined using a commercial
available ELISA kit.
Results: (1) Compared with that of statin monotherapy, statin-bezafibrate combination treatment not only resulted
in a significant reduction of TG, TC and LDL-C levels, (all p < 0.05), but also led to increases in HDL-C and apoA5
levels (p < 0.05).
(2) The percentage changes of TC, TG, LDL-C and apoA5 levels in both groups were even bigger at 12 weeks after
treatment than that at 6 weeks (all p < 0.05). Similarly, the rates of achieving lipid-control target were higher in
statin-bezafibrate combination treatment group than those in statin monotherapy group (all p < 0.05).
(3) Spearman rank correlation analysis showed that the pre-treatment apoA5 level was positively correlated with TG
(r = 0.359, p = 0.009). However, a negative correlation was observed between apoA5 and TG (r = −0.329, p = 0.017)
after 12 weeks treatment.
Conclusions: Statin and fibrate combination therapy is more effective than statin alone in achieving a
comprehensive lipid control for ACS patients. Serum apoA5 elevation after statin and fibrate combination treatment
could be due to the synergistic effect of both drugs on hypertriglyceridemia control.
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Despite using intensive statin therapy, about 65% of
coronary events can not be prevented in patients with
coronary heart diseases. It was believed that the residual
cardiovascular risk was partly associated with atherogenic
dyslipidemia, including elevated triglycerides (TG) and
lower high-density lipoprotein cholesterol (HDL-C) [1].
The atherogenic dyslipidemia is likely to be controlled by* Correspondence: zhaosp@medmail.com.cn
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reproduction in any medium, provided the orthe statin-fibrate combination therapy [2], since fibrates
have more obvious effects on elevated TG and decreased
HDL-C. Interestingly, the combination therapy would
have clinical significance in the setting of acute coronary
syndrome (ACS), which is often characterized by higher
incidence of elevated TG and decreased HDL-C than
stable coronary heart disease [3]. Recent data have shown
that the elevation of plasma TG in ACS patients is asso-
ciated with apolipoprotein A5 (apoA5), a manifest factor
indicating triglyceride metabolism [4,5]. It is noted that
accumulated evidences have demonstrated that bothhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[6-10].
Therefore, the present study was to observe the effects
of statin and fibrate combination treatment on serum
lipids and apoA5 levels in patients with ACS.
Methods
Subjects and study design
The study recruited 104 ACS patients (66 men, 38 women,
mean age of 59.9 ± 7.0 years) in our hospital. Diagnostic
criteria for unstable angina (UA) and acute myocardial in-
farction (AMI) respectively referred to the related guide-
lines of American College of Cardiology/American Heart
Association published in 2007 (For details, please see:
①http://circ.ahajournals.org/cgi/content/full/117/2/296;
and ② http://circ.ahajournals.org/content/116/7/803).
Briefly, the patients were diagnosed as ACS if they had
acute chest pain and changes in consecutive ECG records,
with (AMI) or without (UA) changes of cardiac bio-
markers such as creatine kinase (CK), CK-MB and/or tro-
ponins. Furthermore, the enrolled subjects should have
their TG ≥1.70 mmol/L, LDL-C ≥2.60 mmol/L, and/or
HDL-C <1.04 mmol/L. Exclusion criteria were (1) severe
hepatic or/and renal diseases; (2) severe heart failure; (3)
recent (<2 months) infection, immunologic disorders, thy-
roid diseases, recent major trauma, or cancer; (4) treat-
ment with immunosuppressive or antiinflammatory
agents; and (5) recent treatment with lipid-lowering drugs.
Since the combination of statin and bezafibrate could in-
crease the risk of myopathy or even rhabdomyolysis, sub-
jects who had been previously diagnosed with myopathy
or had high risk of these diseases were also excluded.
All patients enrolled were randomized within 48 h of
hospitalization and before percutaneous coronary inter-
vention (PCI) into two groups: (1) statin group, treated
with atorvastatin 20 mg QN (or other statins in equivalent
dosage, such as rosuvastatin 10 mg QN); (2) combination
group, treated with the same dosage of above-mentioned
statins and bezafibrate 200 mg BID. Also, according to the
related guidelines of American College of Cardiology/
American Heart Association, all subjects were given opti-
mal medical therapy including aspirin, clopidogrel, ACEI/
ARB, beta receptor inhibitor, and/or PCI. Follow-up visits
were scheduled at the end of 6 and 12 weeks after treat-
ment. Our study carried out on humans was in com-
pliance with the Helsinki Declaration and approved by
the Ethics Committee of the Second Xiangya Hospital of
Central South University.
Clinical and laboratory measurements
Serum samples were obtained at randomization and the
end of 6 and 12 weeks thereafter. Follow-up assessments
included laboratory tests, pill counts, and structured in-
terviews assessing outcomes and potential adverseevents. The serum levels of lipids, high-sensitivity C-
reactive protein (hs-CRP), and fasting blood glucose, as
well as hepatic and renal functions, were detected in the
central laboratory of our hospital. Serum apoA5 con-
centration was measured by a sandwich enzyme-linked
immunosorbent assay (ELISA) developed by us using
monoclonal antibodies that had a lower limit of detec-
tion of 0.3 ng/ml and a linear results up to 20 ng/ml.
The ELISA procedure for apoA5 detecting was perfor-
med as previously described [11].
Statistical analysis
Descriptive statistics was used for all data analyses. For
enumeration data, frequency was described and Chi-
square test was used for analyses. For quantitative data
analyses, mean ± SD was described. If the quantitative
data were not normally distributed, rank sum test was
used, while t-test or approximate t-test was used in
normally distributed data. Repeated measures ANOVA
analyses were performed to determine the effects of both
interventions and duration of treatment. The correlation
analysis was performed by Spearman rank correlation.
Differences were considered significant at a value of
p < 0.05 for all tests.
Results
Clinical characteristics of study subjects
The baseline clinical characteristics of subjects enrolled
are summarized in Table 1. There were no significant dif-
ferences between two groups in ACS type (AMI/UA), gen-
der, age, body mass index, blood glucose, blood pressure,
alanine aminotransferase, creatinine, and creatine kinase.
Besides, no significant differences were observed between
two groups in serum levels of lipids (including TG, total
cholesterol, LDL-C and HDL-C), apoA5, and hs-CRP.
Effects of two treatments on lipids, apoA5 and hs-CRP
At the end of study, both groups experienced significant
reductions in TG, TC, LDL-C, and hs-CRP, and in-
creases in HDL-C levels from the baseline. Compared
with statin group, the statin-bezafibrate combination
treatment group resulted insignificantly greater reduc-
tions in TG, TC, and LDL-C, and more increase in
HDL-C (all p < 0.05). No significant difference was ob-
served in hs-CRP between two groups. Both groups
witnessed significantly greater changes in lipids levels
after 12 weeks than 6 weeks (all p < 0.05), but the hs-
CRP levels were similar at the two follow-up time points.
Of note, the apoA5 levels increased in two groups,
with a significantly greater elevation in the combina-
tion group (p < 0.05). Moreover, further increases in
apoA5 levels in both groups were shown after 12 weeks
(p < 0.05) (Table 2).






AMI/ UA (n) 27/25 30/22 0.144
Gender (male/female) 16/36 20/32 0.101
Age (years) 60 ± 6 59 ± 8 0.356
Body mass index (kg/m2) 23.48 ± 1.67 23.94 ± 2.09 0.233
Systolic blood
pressure (mmHg)
131 ± 11 133 ± 12 0.195
Diastolic blood
pressure (mmHg)
76 ± 8 75 ± 9 0.471
Fasting blood
glucose (mmol/L)
5.45 ± 0.66 5.62 ± 0.95 0.263
ALT (u/L) 31.57 ± 21.06 29.08 ± 16.67 0.688
Cr (μmol/L) 87.4 ± 21.67 86.03 ± 18.84 0.728
CK (u/L) 86.01 ± 22.91 87.13 ± 46.38 0.875
TG (mmol/L) 1.97 ± 1.02 1.91 ± 0.87 0.740
TC (mmol/L) 4.85 ± 0.90 4.92 ± 0.83 0.644
LDL-C (mmol/L) 3.00 ± 0.43 3.04 ± 0.46 0.686
HDL-C (mmol/L) 0.89 ± 0.22 0.93 ± 0.14 0.317
Apo A5 (ng/ml) 49.49 ± 1.59 49.50 ± 2.48 0.980
hs-CRP (mg/L) 3.97 ± 3.52 3.89 ± 2.96 0.904
Note: AMI acute myocardial infarction, UA unstable angina, ALT alanine
aminotransferase, Cr creatinine, CK creatine kinase, TG triglycerides, TC total
cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density
lipoprotein cholesterol, ApoA5 apolipoprotein A5, hs-CRP high-sensitivity
C-reactive protein.
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after 12 weeks
In order to compare the lipid-control efficacy of the two
treatments, two endpoints of this study had been consi-
dered, including the percentage change in lipids levels
and the percentage of patients achieving the therapeutic
goal of dyslipidemia. Both groups had significant per-
centage changes in lipids levels after 12 weeks from
baseline (all p < 0.05). As compared with the statin
group, significantly greater reductions in TC, TG, andTable 2 Changes of serum lipids, apoA5 and hs-CRP levels in
Baseline After 6 we
Statin group Combination group Statin gro
TC (mmol/L) 4.85 ± 0.90 4.92 ± 0.83 4.22 ± 0.88*
TG (mmol/L) 1.97 ± 1.02 1.91 ± 0.87 1.74 ± 0.71*
LDL-C (mmol/L) 3.00 ± 0.43 3.04 ± 0.46 2.30 ± 0.53*
HDL-C (mmol/L) 0.89 ± 0.22 0.93 ± 0.14 1.00 ± 0.26*
ApoA5 (ng/ml) 49.49 ± 1.59 49.50 ± 2.48 61.48 ± 6.00
Hs-CRP (mg/L) 3.97 ± 3.52 3.89 ± 2.96 2.01 ± 0.94*
Note: TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein cholestero
hs-CRP high-sensitivity C-reactive protein.
* p < 0.05, compared with baseline in the same group;
† p < 0.05, compared with 6 weeks in the same group;
§ p < 0.05, combination group versus statin group by repeated measures ANOVA anLDL-C levels were observed in the combination group
(all p < 0.05). However, the percentage changes in HDL-C
levels had no significant difference between two groups
(p > 0.05) (Figure 1).
According to 2007 guidelines for the prevention and
treatment of dyslipidemia in Chinese adults, the percent-
ages of ACS patients achieving the following lipid-control
target values were calculated: ①LDL-C <2.07 mmol/L
(80 mg/dL); ②TG <1.70 mmol/L (150 mg/dL); ③ HDL-
C ≥1.04 mmol/L (40 mg/dL). After 12 weeks of treatment,
the percentages of patients achieving the target levels of
LDL-C, TG, and HDL-C were higher in the combination
group than in the statin group (all p < 0.05). Of note, the
percentage of patients achieving the triple lipids targets
(simultaneously achieving the target levels of LDL-C,TG
and HDL-C) in the combination group was much higher
than that in the statin group (7.7% versus 46.2%, p < 0.05)
(Figure 2).
Correlation of apoA5 with other parameters before and
after treatment
Before treatment, Spearman rank correlation analysis
conducted in all subjects showed a significant positive
correlation between apoA5 and TG (r = 0.359, p = 0.009).
However, there was no evidence of any association
between apoA5 and other variables such as TC,
LDL-C, HDL-C and hs-CRP. After 12-week treat-
ment, significant negative correlations of apoA5 with
TG (r = −0.329, p = 0.017), TC (r = −0.394, p = 0.004)
and LDL-C (r = −0.302, p = 0.024) were observed. But
neither HDL-C nor hs-CRP was found to be significantly
correlated with apoA5 (Table 3).
Adverse events
During the whole study period, there were no severe
adverse events reported, such as severe myalgia, liver
damage, renal failure, or rhabdomyolysis. No discontinu-
ation of the study medication occurred due to adverse
events. No significantly higher incidence of adversetwo groups
eks After 12 weeks
up Combination group Statin group Combination group
3.75 ± 0.65 * 4.12 ± 0.76† 3.39 ± 0.30†§
1.24 ± 0.54 * 1.62 ± 0.63† 1.15 ± 0.48†§
2.06 ± 0.28 * 2.21 ± 0.55† 1.93 ± 0.29†§
1.10 ± 0.13 * 1.05 ± 0.20† 1.14 ± 0.08†§
* 66.03 ± 8.79* 67.4 ± 5.50† 73.2 ± 6.67†§
1.61 ± 0.32* 2.03 ± 1.54* 1.62 ± 0.63*
l, HDL-C high-density lipoprotein cholesterol, ApoA5 apolipoprotein A5,
alyses.
Figure 1 Percentage change from baseline in lipids. * p < 0.05,
12 week versus baseline in the same group; § p < 0.05, combination
group versus statin group.
Table 3 Pre- and post-treatment correlation of apoA5
with other parameters













Note: TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein
cholesterol, HDL-C high-density lipoprotein cholesterol, ApoA5 apolipoprotein
A5, hs-CRP high-sensitivity C-reactive protein.
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the statin group. Furthermore, both treatment groups
resulted in no significant elevation in serum levels of
ALT, CK and Cr (Table 4).
Discussion
Dyslipidemia is an established risk factor for the deve-
lopment of coronary heart disease. Although statin ther-
apy is the current recommended primary treatment for
dyslipidemia, many patients fail to reach adequate lipid-
control goals and remain at a significantly increased risk
of cardiovascular events [1,2]. Given this residual risk,
there is a critical need for additional lipid-control
therapies that could augment the efficacy of statins to
further lower the burden of residual atherogenic dyslipi-
demia including elevated TG and low HDL-C level.
Statin-fibrate combination therapy has much clinical
significance for ACS patients with elevated TG and
decreased HDL-C [3]. In the present study, we demon-
strated that the statin-fibrate combination therapy
resulted in greater reductions of TG, TC and LDL-C (all
p < 0.05) and more increase of HDL-C in ACS patientsFigure 2 Percentage of patients achieving therapeutic goal in
lipids. * p < 0.05. 12 week versus baseline in the group; § p < 0.05,
combination group versus statin group. Triple, three lipids biomarker
including LDL-C,TG and HDL-C.(p < 0.05). Moreover, the rate of achieving therapeutic
goal of triple lipids (LDL-C,TG and HDL-C levels) in
patients with combination treatment after 12 weeks was
much higher than that with statin treatment (7.7% versus
46.2%, p < 0.05, Figure 2). Thus, our results suggest that
the combination of statin and fibrate has synergetic effect
of lipid regulation which contributes to improve statin-
associated residual dyslipidemia, especially in ACS pa-
tients with hypertriglyceridemia and/or low HDL-C.
The present study further determined the role of
apoA5 in triglyceride-lowering effect by statin-fibrate
combination. We found that both treatments contri-
buted to the elevation of apoA5 level, with greater eleva-
tion noted in the combination treatment. Interestingly, a
positive correlation has been observed between apoA5
and TG before treatment. However, after 12-week treat-
ment, a negative correlation between apoA5 and TG was
noted. Evidences from genetically engineered mice stud-
ies have shown that apoA5 is a potential factor of plasma
TG reduction. Plasma TG level increased four-fold in
endogenous apoA5 gene deficiency mice and decreased
by 65% on expression of human apoA5 gene [4]. Simi-
larly, inherited apoA5 gene deficiency is associated with
severe hypertriglyceridemia in human [12]. However,Table 4 Pre- and post-treatment serum levels of ALT, CK
and Cr









CK (u/L) 86.01 ± 22.91 87.13 ± 46.38 94.43 ± 27.06 93.63 ± 33.62
ALT (u/L) 31.57 ± 1.06 29.08 ± 16.67 29.75 ± 12.92 31.39 ± 12.49
Cr (μmol/L) 87.40 ± 21.67 86.03 ± 18.84 83.60 ± 18.10 82.83 ± 10.47
Note: CK creatine kinase, ALT alanine aminotransferase, Cr creatinine.
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bearing nonsense apoA5 gene mutations and studies in
genetically engineered mice, the results from the Epic-
Norfolk Population Study showed that plasma apoA5
level was positively correlated with plasma TG [13].
Besides, a positive correlation between apoA5 and TG
was also observed in patients with type 2 diabetes [10].
Our previous study in ACS patients had also observed
such positive correlation before lipid-lowering treatment
[14], but the mechanism is quite unclear. We presume
that plasma apoA5 level may have compensatory in-
crease and the effect of apoA5 on reducing TG level
may be impaired during acute inflammation or stress
state. Together, these findings from human studies indi-
cate a complex relationship between plasma apoA5 and
TG in humans. Nonetheless, our findings in this study
implicated a role of apoA5 in plasma TG reduction by
statins and/or fibrates. It is well documented that
fibrates, agonist of PPARα, result in plasma TG re-
duction by upregulating apoA5 expression. A PPAR
response element has been identified at the transcription
start site of apoA5 gene, whereby pharmacological PPAR
agonists (such as fibrates) may exert their beneficial
hypotriglyceridemic actions [6,7]. Our previous findings
indicated that statin and fibrate synergistically increased
apoA5 and decreased TG by upregulating PPARα in rats
[9]. Therefore, we conclude that statin and fibrate can
synergistically increase plasma apoA5 level, which re-
sults in more hypotriglyceridemic effects.
Atherosclerosis is an inflammatory disease and acute
inflammation is a major factor underlying the develop-
ment of ACS [15]. In the acute inflammatory setting of
ACS, lipid and lipoprotein metabolism experiences sys-
temic alteration including elevated TG and decreased
HDL-C [16]. Furthermore, apoA5 gene is regulated by
proinflammatory cytokines and apoA5 may be involved
in inflammation-associated hypertriglyceridemia [17,18].
Therefore, we examined the potential cross-talk between
inflammation and apoA5 in ACS. Our findings demon-
strated that both treatments could lead to the reduction
of hs-CRP, an inflammatory biomarker. This suggests
that both lipid-lowering agents can inhibit inflammatory
reaction, and contribute to lower incidence of cardiovas-
cular events [19]. However, no significant correlation
was found between apoA5 and hs-CRP in our present
study. Our findings indicated that elevation of serum
apoA5 level by statin or fibrate could be independent
from their anti-inflammatory effect.
In general, statin and fibrate combination therapy is
more effective than statin monotherapy in achieving a
comprehensive lipid control target for ACS patients.
Furthermore, our data suggest that the synergy of the
combination therapy in reducing triglyceride may be
involved with the elevation of apoA5 level.Consent
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